PT  - JOURNAL ARTICLE
AU  - Bakkila, Baylee F.
AU  - Basu, Sanjay
AU  - Lipska, Kasia J.
TI  - Out of Pocket Spending on Insulin under $35 Copayment Caps
AID  - 10.1101/2022.12.21.22283784
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.12.21.22283784
4099  - http://medrxiv.org/content/early/2022/12/21/2022.12.21.22283784.short
4100  - http://medrxiv.org/content/early/2022/12/21/2022.12.21.22283784.full
AB  - The high cost of insulin has made it inaccessible to many patients who need it. The Inflation Reduction Act (IRA), which was recently signed into law, limits out of pocket (OOP) spending on insulin to $35 for a 30-day supply for individuals covered by Medicare. In this study, we estimate substantial OOP savings for individuals who require insulin, finding that Medicare-insured persons are projected to save nearly one-fifth of their expenditures on insulin.Competing Interest StatementSB reports funding from the National Center for Chronic Disease Prevention and Health Promotion (U18DP006526), the National Institute of Diabetes and Digestive and Kidney Diseases (P30DK092924, R01DK116852), and personal fees from the University of California San Francisco, Waymark and HealthRight 360. KL reports grants from the National Institutes Health and royalties from UpToDate where she writes/edits content. BB reports no conflicts of interest.Funding StatementSB reports funding from the National Center for Chronic Disease Prevention and Health Promotion (U18DP006526), the National Institute of Diabetes and Digestive and Kidney Diseases (P30DK092924, R01DK116852), and personal fees from the University of California San Francisco, Waymark and HealthRight 360. KL reports grants from the National Institutes Health and royalties from UpToDate where she writes/edits content. BB reports no conflicts of interest.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human data that were originally located at: https://www.meps.ahrq.gov/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://www.meps.ahrq.gov/